p21 Expression and p53 Status in Breast Cancer
Author Information
Author(s): PA Ellis, PE Lonning, A Borresen-Dale, T Aas, S Geisler, LA Akslen, I Salter, IE Smith, M Dowsett
Primary Institution: Royal Marsden Hospital
Hypothesis
Does p21 protein expression act as a downstream marker of tumors from patients with locally advanced breast cancer before treatment with doxorubicin?
Conclusion
The study found that p21 protein expression is inversely associated with abnormal p53 protein in human breast cancer.
Supporting Evidence
- 31 out of 56 patients expressed p21 protein.
- 90% of p21 positive patients had low negative p53 expression.
- Only 23% of patients with high p53 expressed p21.
Takeaway
This study looked at how two proteins, p21 and p53, behave in breast cancer. It found that when p21 is present, p53 is often not working properly.
Methodology
The study involved immunostaining and DNA mutational analysis of p53 and p21 in tumor samples from breast cancer patients before treatment.
Limitations
The study did not find a significant relationship between p21 expression and clinical response to chemotherapy.
Participant Demographics
Median age was 64 years (range 32-85 years); all patients had locally advanced breast cancer.
Statistical Information
P-Value
0.009
Confidence Interval
95% CI 48-79%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website